Abstract Background New emerging infections have no known treatment. Assessing potential drugs for safety and efficacy enables clinicians to make evidence-based treatment decisions and contributes to overall outbreak control. However. it is difficult to launch clinical trials in the unpredictable environment of an outbreak. https://www.dawnsdinners.com/product-category/gift-cards/